Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID‐19 pandemic
The COVID‐19 pandemic poses a unique challenge to the care of patients with haematological malignancies. Viral pneumonia is known to cause disproportionately severe disease in patients with cancer, and patients with lymphoma, myeloma and chronic lymphocytic leukaemia are likely to be at particular r...
Gespeichert in:
| Veröffentlicht in: | Internal medicine journal 2020-06, Vol.50 (6), p.667-679 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 679 |
|---|---|
| container_issue | 6 |
| container_start_page | 667 |
| container_title | Internal medicine journal |
| container_volume | 50 |
| creator | Di Ciaccio, Pietro McCaughan, Georgia Trotman, Judith Ho, Phoebe Joy Cheah, Chan Y. Gangatharan, Shane Wight, Joel Ku, Matthew Quach, Hang Gasiorowski, Robin Polizzotto, Mark N. Prince, Henry Miles Mulligan, Stephen Tam, Constantine S. Gregory, Gareth Hapgood, Greg Spencer, Andrew Dickinson, Michael Latimer, Maya Johnston, Anna Armytage, Tasman Lee, Cindy Cochrane, Tara Berkhahn, Leanne Weinkove, Robert Doocey, Richard Harrison, Simon J. Webber, Nicholas Lee, Hui‐Peng Chapman, Scott Campbell, Belinda A. Gibbs, Simon D. J. Hamad, Nada |
| description | The COVID‐19 pandemic poses a unique challenge to the care of patients with haematological malignancies. Viral pneumonia is known to cause disproportionately severe disease in patients with cancer, and patients with lymphoma, myeloma and chronic lymphocytic leukaemia are likely to be at particular risk of severe disease related to COVID‐19. This statement has been developed by consensus among authors from Australia and New Zealand. We aim to provide supportive guidance to clinicians making individual patient decisions during the COVID‐19 pandemic, in particular during periods that access to healthcare resources may be limited. General recommendations include those to minimise patient exposure to COVID‐19, including the use of telehealth, avoidance of non‐essential visits and minimisation of time spent by patients in infusion suites and other clinical areas. This statement also provides recommendations where appropriate in assessing indications for therapy, reducing therapy‐associated immunosuppression and reducing healthcare utilisation in patients with specific haematological malignancies during the COVID‐19 pandemic. Specific decisions regarding therapy of haematological malignancies will need to be individualised, based on disease risk, risks of immunosuppression, rates of community transmission of COVID‐19 and available local healthcare resources. |
| doi_str_mv | 10.1111/imj.14859 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2404048285</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2404048285</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3889-cc2b3031ba628b15df06c1d6322c5af4144be17484ba066c372f872e0705f1153</originalsourceid><addsrcrecordid>eNp1kctO3DAUhq2qqAyXRV8AWeoGJAK-JXGWo4HCIAqblkU3keOczGQaO4OdaJRdH4EVD9gnqecCi0r1WfjX0af_2OdH6DMlFzScy9osLqiQcfYBjagQcRRnmfi40SIiGeH76MD7BSE05Zn4hPY5EzROGR-h13HvO6eaWlmsbIkfYIV_gmrWWrfWg_W9x75THRiwHW4t7uaAjbJqtutUuBnMct4adY713LW21ruOHrq1hv6XAlOrzQAzQBNQXPautrON2eTxaXr15_cLzfAyIAHVR2ivUo2H4919iH58vf4-uY3uH2-mk_F9pLmUWaQ1KzjhtFAJkwWNy4okmpYJZ0zHqhJhAQXQVEhRKJIkmqeskikDkpK4ojTmh-h067t07XMPvstN7TU04f_Q9j5ngoSSTK7RL_-gi7Z3NrwuUJSlIpVUBOpsS2nXeu-gypeuNsoNOSX5Oqw8hJVvwgrsyc6xLwyU7-RbOgG43AKruoHh_0759Nvd1vIvu0iffQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2412747814</pqid></control><display><type>article</type><title>Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID‐19 pandemic</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Di Ciaccio, Pietro ; McCaughan, Georgia ; Trotman, Judith ; Ho, Phoebe Joy ; Cheah, Chan Y. ; Gangatharan, Shane ; Wight, Joel ; Ku, Matthew ; Quach, Hang ; Gasiorowski, Robin ; Polizzotto, Mark N. ; Prince, Henry Miles ; Mulligan, Stephen ; Tam, Constantine S. ; Gregory, Gareth ; Hapgood, Greg ; Spencer, Andrew ; Dickinson, Michael ; Latimer, Maya ; Johnston, Anna ; Armytage, Tasman ; Lee, Cindy ; Cochrane, Tara ; Berkhahn, Leanne ; Weinkove, Robert ; Doocey, Richard ; Harrison, Simon J. ; Webber, Nicholas ; Lee, Hui‐Peng ; Chapman, Scott ; Campbell, Belinda A. ; Gibbs, Simon D. J. ; Hamad, Nada</creator><creatorcontrib>Di Ciaccio, Pietro ; McCaughan, Georgia ; Trotman, Judith ; Ho, Phoebe Joy ; Cheah, Chan Y. ; Gangatharan, Shane ; Wight, Joel ; Ku, Matthew ; Quach, Hang ; Gasiorowski, Robin ; Polizzotto, Mark N. ; Prince, Henry Miles ; Mulligan, Stephen ; Tam, Constantine S. ; Gregory, Gareth ; Hapgood, Greg ; Spencer, Andrew ; Dickinson, Michael ; Latimer, Maya ; Johnston, Anna ; Armytage, Tasman ; Lee, Cindy ; Cochrane, Tara ; Berkhahn, Leanne ; Weinkove, Robert ; Doocey, Richard ; Harrison, Simon J. ; Webber, Nicholas ; Lee, Hui‐Peng ; Chapman, Scott ; Campbell, Belinda A. ; Gibbs, Simon D. J. ; Hamad, Nada</creatorcontrib><description>The COVID‐19 pandemic poses a unique challenge to the care of patients with haematological malignancies. Viral pneumonia is known to cause disproportionately severe disease in patients with cancer, and patients with lymphoma, myeloma and chronic lymphocytic leukaemia are likely to be at particular risk of severe disease related to COVID‐19. This statement has been developed by consensus among authors from Australia and New Zealand. We aim to provide supportive guidance to clinicians making individual patient decisions during the COVID‐19 pandemic, in particular during periods that access to healthcare resources may be limited. General recommendations include those to minimise patient exposure to COVID‐19, including the use of telehealth, avoidance of non‐essential visits and minimisation of time spent by patients in infusion suites and other clinical areas. This statement also provides recommendations where appropriate in assessing indications for therapy, reducing therapy‐associated immunosuppression and reducing healthcare utilisation in patients with specific haematological malignancies during the COVID‐19 pandemic. Specific decisions regarding therapy of haematological malignancies will need to be individualised, based on disease risk, risks of immunosuppression, rates of community transmission of COVID‐19 and available local healthcare resources.</description><identifier>ISSN: 1444-0903</identifier><identifier>EISSN: 1445-5994</identifier><identifier>DOI: 10.1111/imj.14859</identifier><identifier>PMID: 32415723</identifier><language>eng</language><publisher>Melbourne: John Wiley & Sons Australia, Ltd</publisher><subject>Australia ; Betacoronavirus - immunology ; chronic lymphocytic leukaemia ; Chronic lymphocytic leukemia ; Comorbidity ; Consensus ; Coronavirus Infections - epidemiology ; Coronavirus Infections - immunology ; Coronavirus Infections - prevention & control ; Coronavirus Infections - virology ; COVID-19 ; Drug Therapy ; Guideline Adherence ; Hematology ; Humans ; Immunosuppression ; Infection Control - methods ; Leukemia ; Leukemia, Lymphocytic, Chronic, B-Cell - immunology ; Leukemia, Lymphocytic, Chronic, B-Cell - physiopathology ; Leukemia, Lymphocytic, Chronic, B-Cell - therapy ; Lymphoma ; Lymphoma - immunology ; Lymphoma - physiopathology ; Lymphoma - therapy ; Multiple myeloma ; Multiple Myeloma - immunology ; Multiple Myeloma - physiopathology ; Multiple Myeloma - therapy ; Myeloma ; New Zealand ; Pandemics ; Pandemics - prevention & control ; Patients ; Pneumonia, Viral - epidemiology ; Pneumonia, Viral - immunology ; Pneumonia, Viral - prevention & control ; Pneumonia, Viral - virology ; Practice Guidelines as Topic ; Risk Assessment ; Salvage Therapy - methods ; SARS-CoV-2 ; Stem Cell Transplantation - methods</subject><ispartof>Internal medicine journal, 2020-06, Vol.50 (6), p.667-679</ispartof><rights>2020 Royal Australasian College of Physicians</rights><rights>2020 Royal Australasian College of Physicians.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3889-cc2b3031ba628b15df06c1d6322c5af4144be17484ba066c372f872e0705f1153</citedby><cites>FETCH-LOGICAL-c3889-cc2b3031ba628b15df06c1d6322c5af4144be17484ba066c372f872e0705f1153</cites><orcidid>0000-0001-7988-1565 ; 0000-0002-1492-5966 ; 0000-0002-9289-1335 ; 0000-0002-7980-8496 ; 0000-0003-1225-8757 ; 0000-0002-9282-8619 ; 0000-0001-8009-4593 ; 0000-0001-7929-1450</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fimj.14859$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fimj.14859$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32415723$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Di Ciaccio, Pietro</creatorcontrib><creatorcontrib>McCaughan, Georgia</creatorcontrib><creatorcontrib>Trotman, Judith</creatorcontrib><creatorcontrib>Ho, Phoebe Joy</creatorcontrib><creatorcontrib>Cheah, Chan Y.</creatorcontrib><creatorcontrib>Gangatharan, Shane</creatorcontrib><creatorcontrib>Wight, Joel</creatorcontrib><creatorcontrib>Ku, Matthew</creatorcontrib><creatorcontrib>Quach, Hang</creatorcontrib><creatorcontrib>Gasiorowski, Robin</creatorcontrib><creatorcontrib>Polizzotto, Mark N.</creatorcontrib><creatorcontrib>Prince, Henry Miles</creatorcontrib><creatorcontrib>Mulligan, Stephen</creatorcontrib><creatorcontrib>Tam, Constantine S.</creatorcontrib><creatorcontrib>Gregory, Gareth</creatorcontrib><creatorcontrib>Hapgood, Greg</creatorcontrib><creatorcontrib>Spencer, Andrew</creatorcontrib><creatorcontrib>Dickinson, Michael</creatorcontrib><creatorcontrib>Latimer, Maya</creatorcontrib><creatorcontrib>Johnston, Anna</creatorcontrib><creatorcontrib>Armytage, Tasman</creatorcontrib><creatorcontrib>Lee, Cindy</creatorcontrib><creatorcontrib>Cochrane, Tara</creatorcontrib><creatorcontrib>Berkhahn, Leanne</creatorcontrib><creatorcontrib>Weinkove, Robert</creatorcontrib><creatorcontrib>Doocey, Richard</creatorcontrib><creatorcontrib>Harrison, Simon J.</creatorcontrib><creatorcontrib>Webber, Nicholas</creatorcontrib><creatorcontrib>Lee, Hui‐Peng</creatorcontrib><creatorcontrib>Chapman, Scott</creatorcontrib><creatorcontrib>Campbell, Belinda A.</creatorcontrib><creatorcontrib>Gibbs, Simon D. J.</creatorcontrib><creatorcontrib>Hamad, Nada</creatorcontrib><title>Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID‐19 pandemic</title><title>Internal medicine journal</title><addtitle>Intern Med J</addtitle><description>The COVID‐19 pandemic poses a unique challenge to the care of patients with haematological malignancies. Viral pneumonia is known to cause disproportionately severe disease in patients with cancer, and patients with lymphoma, myeloma and chronic lymphocytic leukaemia are likely to be at particular risk of severe disease related to COVID‐19. This statement has been developed by consensus among authors from Australia and New Zealand. We aim to provide supportive guidance to clinicians making individual patient decisions during the COVID‐19 pandemic, in particular during periods that access to healthcare resources may be limited. General recommendations include those to minimise patient exposure to COVID‐19, including the use of telehealth, avoidance of non‐essential visits and minimisation of time spent by patients in infusion suites and other clinical areas. This statement also provides recommendations where appropriate in assessing indications for therapy, reducing therapy‐associated immunosuppression and reducing healthcare utilisation in patients with specific haematological malignancies during the COVID‐19 pandemic. Specific decisions regarding therapy of haematological malignancies will need to be individualised, based on disease risk, risks of immunosuppression, rates of community transmission of COVID‐19 and available local healthcare resources.</description><subject>Australia</subject><subject>Betacoronavirus - immunology</subject><subject>chronic lymphocytic leukaemia</subject><subject>Chronic lymphocytic leukemia</subject><subject>Comorbidity</subject><subject>Consensus</subject><subject>Coronavirus Infections - epidemiology</subject><subject>Coronavirus Infections - immunology</subject><subject>Coronavirus Infections - prevention & control</subject><subject>Coronavirus Infections - virology</subject><subject>COVID-19</subject><subject>Drug Therapy</subject><subject>Guideline Adherence</subject><subject>Hematology</subject><subject>Humans</subject><subject>Immunosuppression</subject><subject>Infection Control - methods</subject><subject>Leukemia</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - immunology</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - physiopathology</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - therapy</subject><subject>Lymphoma</subject><subject>Lymphoma - immunology</subject><subject>Lymphoma - physiopathology</subject><subject>Lymphoma - therapy</subject><subject>Multiple myeloma</subject><subject>Multiple Myeloma - immunology</subject><subject>Multiple Myeloma - physiopathology</subject><subject>Multiple Myeloma - therapy</subject><subject>Myeloma</subject><subject>New Zealand</subject><subject>Pandemics</subject><subject>Pandemics - prevention & control</subject><subject>Patients</subject><subject>Pneumonia, Viral - epidemiology</subject><subject>Pneumonia, Viral - immunology</subject><subject>Pneumonia, Viral - prevention & control</subject><subject>Pneumonia, Viral - virology</subject><subject>Practice Guidelines as Topic</subject><subject>Risk Assessment</subject><subject>Salvage Therapy - methods</subject><subject>SARS-CoV-2</subject><subject>Stem Cell Transplantation - methods</subject><issn>1444-0903</issn><issn>1445-5994</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kctO3DAUhq2qqAyXRV8AWeoGJAK-JXGWo4HCIAqblkU3keOczGQaO4OdaJRdH4EVD9gnqecCi0r1WfjX0af_2OdH6DMlFzScy9osLqiQcfYBjagQcRRnmfi40SIiGeH76MD7BSE05Zn4hPY5EzROGR-h13HvO6eaWlmsbIkfYIV_gmrWWrfWg_W9x75THRiwHW4t7uaAjbJqtutUuBnMct4adY713LW21ruOHrq1hv6XAlOrzQAzQBNQXPautrON2eTxaXr15_cLzfAyIAHVR2ivUo2H4919iH58vf4-uY3uH2-mk_F9pLmUWaQ1KzjhtFAJkwWNy4okmpYJZ0zHqhJhAQXQVEhRKJIkmqeskikDkpK4ojTmh-h067t07XMPvstN7TU04f_Q9j5ngoSSTK7RL_-gi7Z3NrwuUJSlIpVUBOpsS2nXeu-gypeuNsoNOSX5Oqw8hJVvwgrsyc6xLwyU7-RbOgG43AKruoHh_0759Nvd1vIvu0iffQ</recordid><startdate>202006</startdate><enddate>202006</enddate><creator>Di Ciaccio, Pietro</creator><creator>McCaughan, Georgia</creator><creator>Trotman, Judith</creator><creator>Ho, Phoebe Joy</creator><creator>Cheah, Chan Y.</creator><creator>Gangatharan, Shane</creator><creator>Wight, Joel</creator><creator>Ku, Matthew</creator><creator>Quach, Hang</creator><creator>Gasiorowski, Robin</creator><creator>Polizzotto, Mark N.</creator><creator>Prince, Henry Miles</creator><creator>Mulligan, Stephen</creator><creator>Tam, Constantine S.</creator><creator>Gregory, Gareth</creator><creator>Hapgood, Greg</creator><creator>Spencer, Andrew</creator><creator>Dickinson, Michael</creator><creator>Latimer, Maya</creator><creator>Johnston, Anna</creator><creator>Armytage, Tasman</creator><creator>Lee, Cindy</creator><creator>Cochrane, Tara</creator><creator>Berkhahn, Leanne</creator><creator>Weinkove, Robert</creator><creator>Doocey, Richard</creator><creator>Harrison, Simon J.</creator><creator>Webber, Nicholas</creator><creator>Lee, Hui‐Peng</creator><creator>Chapman, Scott</creator><creator>Campbell, Belinda A.</creator><creator>Gibbs, Simon D. J.</creator><creator>Hamad, Nada</creator><general>John Wiley & Sons Australia, Ltd</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7988-1565</orcidid><orcidid>https://orcid.org/0000-0002-1492-5966</orcidid><orcidid>https://orcid.org/0000-0002-9289-1335</orcidid><orcidid>https://orcid.org/0000-0002-7980-8496</orcidid><orcidid>https://orcid.org/0000-0003-1225-8757</orcidid><orcidid>https://orcid.org/0000-0002-9282-8619</orcidid><orcidid>https://orcid.org/0000-0001-8009-4593</orcidid><orcidid>https://orcid.org/0000-0001-7929-1450</orcidid></search><sort><creationdate>202006</creationdate><title>Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID‐19 pandemic</title><author>Di Ciaccio, Pietro ; McCaughan, Georgia ; Trotman, Judith ; Ho, Phoebe Joy ; Cheah, Chan Y. ; Gangatharan, Shane ; Wight, Joel ; Ku, Matthew ; Quach, Hang ; Gasiorowski, Robin ; Polizzotto, Mark N. ; Prince, Henry Miles ; Mulligan, Stephen ; Tam, Constantine S. ; Gregory, Gareth ; Hapgood, Greg ; Spencer, Andrew ; Dickinson, Michael ; Latimer, Maya ; Johnston, Anna ; Armytage, Tasman ; Lee, Cindy ; Cochrane, Tara ; Berkhahn, Leanne ; Weinkove, Robert ; Doocey, Richard ; Harrison, Simon J. ; Webber, Nicholas ; Lee, Hui‐Peng ; Chapman, Scott ; Campbell, Belinda A. ; Gibbs, Simon D. J. ; Hamad, Nada</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3889-cc2b3031ba628b15df06c1d6322c5af4144be17484ba066c372f872e0705f1153</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Australia</topic><topic>Betacoronavirus - immunology</topic><topic>chronic lymphocytic leukaemia</topic><topic>Chronic lymphocytic leukemia</topic><topic>Comorbidity</topic><topic>Consensus</topic><topic>Coronavirus Infections - epidemiology</topic><topic>Coronavirus Infections - immunology</topic><topic>Coronavirus Infections - prevention & control</topic><topic>Coronavirus Infections - virology</topic><topic>COVID-19</topic><topic>Drug Therapy</topic><topic>Guideline Adherence</topic><topic>Hematology</topic><topic>Humans</topic><topic>Immunosuppression</topic><topic>Infection Control - methods</topic><topic>Leukemia</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - immunology</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - physiopathology</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - therapy</topic><topic>Lymphoma</topic><topic>Lymphoma - immunology</topic><topic>Lymphoma - physiopathology</topic><topic>Lymphoma - therapy</topic><topic>Multiple myeloma</topic><topic>Multiple Myeloma - immunology</topic><topic>Multiple Myeloma - physiopathology</topic><topic>Multiple Myeloma - therapy</topic><topic>Myeloma</topic><topic>New Zealand</topic><topic>Pandemics</topic><topic>Pandemics - prevention & control</topic><topic>Patients</topic><topic>Pneumonia, Viral - epidemiology</topic><topic>Pneumonia, Viral - immunology</topic><topic>Pneumonia, Viral - prevention & control</topic><topic>Pneumonia, Viral - virology</topic><topic>Practice Guidelines as Topic</topic><topic>Risk Assessment</topic><topic>Salvage Therapy - methods</topic><topic>SARS-CoV-2</topic><topic>Stem Cell Transplantation - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Di Ciaccio, Pietro</creatorcontrib><creatorcontrib>McCaughan, Georgia</creatorcontrib><creatorcontrib>Trotman, Judith</creatorcontrib><creatorcontrib>Ho, Phoebe Joy</creatorcontrib><creatorcontrib>Cheah, Chan Y.</creatorcontrib><creatorcontrib>Gangatharan, Shane</creatorcontrib><creatorcontrib>Wight, Joel</creatorcontrib><creatorcontrib>Ku, Matthew</creatorcontrib><creatorcontrib>Quach, Hang</creatorcontrib><creatorcontrib>Gasiorowski, Robin</creatorcontrib><creatorcontrib>Polizzotto, Mark N.</creatorcontrib><creatorcontrib>Prince, Henry Miles</creatorcontrib><creatorcontrib>Mulligan, Stephen</creatorcontrib><creatorcontrib>Tam, Constantine S.</creatorcontrib><creatorcontrib>Gregory, Gareth</creatorcontrib><creatorcontrib>Hapgood, Greg</creatorcontrib><creatorcontrib>Spencer, Andrew</creatorcontrib><creatorcontrib>Dickinson, Michael</creatorcontrib><creatorcontrib>Latimer, Maya</creatorcontrib><creatorcontrib>Johnston, Anna</creatorcontrib><creatorcontrib>Armytage, Tasman</creatorcontrib><creatorcontrib>Lee, Cindy</creatorcontrib><creatorcontrib>Cochrane, Tara</creatorcontrib><creatorcontrib>Berkhahn, Leanne</creatorcontrib><creatorcontrib>Weinkove, Robert</creatorcontrib><creatorcontrib>Doocey, Richard</creatorcontrib><creatorcontrib>Harrison, Simon J.</creatorcontrib><creatorcontrib>Webber, Nicholas</creatorcontrib><creatorcontrib>Lee, Hui‐Peng</creatorcontrib><creatorcontrib>Chapman, Scott</creatorcontrib><creatorcontrib>Campbell, Belinda A.</creatorcontrib><creatorcontrib>Gibbs, Simon D. J.</creatorcontrib><creatorcontrib>Hamad, Nada</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Internal medicine journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Di Ciaccio, Pietro</au><au>McCaughan, Georgia</au><au>Trotman, Judith</au><au>Ho, Phoebe Joy</au><au>Cheah, Chan Y.</au><au>Gangatharan, Shane</au><au>Wight, Joel</au><au>Ku, Matthew</au><au>Quach, Hang</au><au>Gasiorowski, Robin</au><au>Polizzotto, Mark N.</au><au>Prince, Henry Miles</au><au>Mulligan, Stephen</au><au>Tam, Constantine S.</au><au>Gregory, Gareth</au><au>Hapgood, Greg</au><au>Spencer, Andrew</au><au>Dickinson, Michael</au><au>Latimer, Maya</au><au>Johnston, Anna</au><au>Armytage, Tasman</au><au>Lee, Cindy</au><au>Cochrane, Tara</au><au>Berkhahn, Leanne</au><au>Weinkove, Robert</au><au>Doocey, Richard</au><au>Harrison, Simon J.</au><au>Webber, Nicholas</au><au>Lee, Hui‐Peng</au><au>Chapman, Scott</au><au>Campbell, Belinda A.</au><au>Gibbs, Simon D. J.</au><au>Hamad, Nada</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID‐19 pandemic</atitle><jtitle>Internal medicine journal</jtitle><addtitle>Intern Med J</addtitle><date>2020-06</date><risdate>2020</risdate><volume>50</volume><issue>6</issue><spage>667</spage><epage>679</epage><pages>667-679</pages><issn>1444-0903</issn><eissn>1445-5994</eissn><abstract>The COVID‐19 pandemic poses a unique challenge to the care of patients with haematological malignancies. Viral pneumonia is known to cause disproportionately severe disease in patients with cancer, and patients with lymphoma, myeloma and chronic lymphocytic leukaemia are likely to be at particular risk of severe disease related to COVID‐19. This statement has been developed by consensus among authors from Australia and New Zealand. We aim to provide supportive guidance to clinicians making individual patient decisions during the COVID‐19 pandemic, in particular during periods that access to healthcare resources may be limited. General recommendations include those to minimise patient exposure to COVID‐19, including the use of telehealth, avoidance of non‐essential visits and minimisation of time spent by patients in infusion suites and other clinical areas. This statement also provides recommendations where appropriate in assessing indications for therapy, reducing therapy‐associated immunosuppression and reducing healthcare utilisation in patients with specific haematological malignancies during the COVID‐19 pandemic. Specific decisions regarding therapy of haematological malignancies will need to be individualised, based on disease risk, risks of immunosuppression, rates of community transmission of COVID‐19 and available local healthcare resources.</abstract><cop>Melbourne</cop><pub>John Wiley & Sons Australia, Ltd</pub><pmid>32415723</pmid><doi>10.1111/imj.14859</doi><tpages>120</tpages><orcidid>https://orcid.org/0000-0001-7988-1565</orcidid><orcidid>https://orcid.org/0000-0002-1492-5966</orcidid><orcidid>https://orcid.org/0000-0002-9289-1335</orcidid><orcidid>https://orcid.org/0000-0002-7980-8496</orcidid><orcidid>https://orcid.org/0000-0003-1225-8757</orcidid><orcidid>https://orcid.org/0000-0002-9282-8619</orcidid><orcidid>https://orcid.org/0000-0001-8009-4593</orcidid><orcidid>https://orcid.org/0000-0001-7929-1450</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1444-0903 |
| ispartof | Internal medicine journal, 2020-06, Vol.50 (6), p.667-679 |
| issn | 1444-0903 1445-5994 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2404048285 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Australia Betacoronavirus - immunology chronic lymphocytic leukaemia Chronic lymphocytic leukemia Comorbidity Consensus Coronavirus Infections - epidemiology Coronavirus Infections - immunology Coronavirus Infections - prevention & control Coronavirus Infections - virology COVID-19 Drug Therapy Guideline Adherence Hematology Humans Immunosuppression Infection Control - methods Leukemia Leukemia, Lymphocytic, Chronic, B-Cell - immunology Leukemia, Lymphocytic, Chronic, B-Cell - physiopathology Leukemia, Lymphocytic, Chronic, B-Cell - therapy Lymphoma Lymphoma - immunology Lymphoma - physiopathology Lymphoma - therapy Multiple myeloma Multiple Myeloma - immunology Multiple Myeloma - physiopathology Multiple Myeloma - therapy Myeloma New Zealand Pandemics Pandemics - prevention & control Patients Pneumonia, Viral - epidemiology Pneumonia, Viral - immunology Pneumonia, Viral - prevention & control Pneumonia, Viral - virology Practice Guidelines as Topic Risk Assessment Salvage Therapy - methods SARS-CoV-2 Stem Cell Transplantation - methods |
| title | Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID‐19 pandemic |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T01%3A13%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Australian%20and%20New%20Zealand%20consensus%20statement%20on%20the%20management%20of%20lymphoma,%20chronic%20lymphocytic%20leukaemia%20and%20myeloma%20during%20the%20COVID%E2%80%9019%20pandemic&rft.jtitle=Internal%20medicine%20journal&rft.au=Di%20Ciaccio,%20Pietro&rft.date=2020-06&rft.volume=50&rft.issue=6&rft.spage=667&rft.epage=679&rft.pages=667-679&rft.issn=1444-0903&rft.eissn=1445-5994&rft_id=info:doi/10.1111/imj.14859&rft_dat=%3Cproquest_cross%3E2404048285%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2412747814&rft_id=info:pmid/32415723&rfr_iscdi=true |